NCT06560255 Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma
| NCT ID | NCT06560255 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Professor Klaus Bønnelykke |
| Condition | Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-12-20 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 2,000 participants in total. It began in 2024-12-20 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall aim of the study is to develop a nutritional preventive fish oil supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that both supplementations in higher doses than recommended could reduce the risk of disease development.
Eligibility Criteria
* Pregnant Danish women before week 26 with blood levels of EPA+DHA below 4.7% of total fatty acids * No planned use of fish oil supplementations * No endocrine-, heart-, kidney- or auto-immune disorders * No disorders requiring treatment with blood thinning medication
Contact & Investigator
Bo Chawes, PhD
PRINCIPAL INVESTIGATOR
Copenhagen Studies on Asthma in Childhood
Frequently Asked Questions
Who can join the NCT06560255 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06560255 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 2,000 participants.
Is NCT06560255 currently recruiting?
Yes, NCT06560255 is actively recruiting participants. Contact the research team at kb@copsac.com for enrollment information.
Where is the NCT06560255 trial being conducted?
This trial is being conducted at Gentofte Municipality, Denmark.
Who is sponsoring the NCT06560255 clinical trial?
NCT06560255 is sponsored by Professor Klaus Bønnelykke. The principal investigator is Bo Chawes, PhD at Copenhagen Studies on Asthma in Childhood. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.